IRD NASDAQ
Opus Genetics, Inc.
1W: -13.7%
1M: -31.5%
3M: -0.3%
YTD: +63.2%
1Y: +73.9%
3Y: +16.5%
5Y: -17.8%
$3.46
+0.14 (+4.22%)
Weekly Expected Move ±9.9%
$3
$3
$3
$4
$4
Credit Risk of going bust: higher than 69% of companies Debt: 10.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.06 (down 98%), Opus Genetics, Inc. would be worth roughly what it owes.
Total debt $34.9M against a stock market value of $287.9M.
Distance to default 3.48 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.5M (short-term plus half of long-term), stock volatility 79.7%; Altman Z'' -10.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.06 (down 98%), Opus Genetics, Inc. would be worth roughly what it owes.
Total debt $34.9M against a stock market value of $287.9M.
Distance to default 3.48 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.5M (short-term plus half of long-term), stock volatility 79.7%; Altman Z'' -10.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships13
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-06-07
Earliest Filing
2025-11-06
Latest Filing
investor: 8
partner: 4
target: 1
Counterparties (Filed by IRD)
13 relationshipsCompanies named in IRD's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | — | investor | Affiliate of purchaser in registered direct offering | 2025-11-06 | View |
| Nantahala Capital Management, LLC | — | investor | Affiliate of purchaser in registered direct offering | 2025-11-06 | View |
| Balyasny Asset Management L.P. | — | investor | Affiliate of purchaser in registered direct offering | 2025-11-06 | View |
| Eyes on the Future | — | investor | Funding party providing up to $1.6M for RDH12 gene therapy development | 2025-07-23 | View |
| RDH12 Fund for Sight | — | investor | Funding party providing up to $1.6M for RDH12 gene therapy development | 2025-07-23 | View |
| Foundation Fighting Blindness Retinal Degeneration Fund | — | investor | Funding agreement for MERTK gene therapy program development | 2025-06-20 | View |
| Foundation Fighting Blindness | — | investor | Significant stockholder and sole member of the funding fund | 2025-06-20 | View |
| Opus Genetics Inc. | IRD | target | Target company acquired by Ocuphire Pharma, Inc. in a merger transaction. | 2024-10-22 | View |
| Lincoln Park Capital Fund, LLC | — | investor | Agreed to purchase up to $50,000,000 of Ocuphire Pharma, Inc. common stock under a common stock purchase agreement. | 2023-08-11 | View |
| FamyGen Life Sciences, Inc. | — | partner | Entered into a License and Collaboration Agreement with Ocuphire Pharma, Inc. to develop and commercialize Nyxol product | 2022-11-07 | View |
| Viatris Inc. | VTRS | partner | Agreed to procure the commercialization of the Products in the Territory for each indication that receives regulatory ap | 2022-11-07 | View |
| Processa Pharmaceuticals, Inc. | PCSA | partner | Ocuphire granted Processa an exclusive license to develop, manufacture and commercialize RX-3117 globally, excluding Chi | 2021-06-23 | View |
| A.G.P./Alliance Global Partners | — | partner | Placement agent for registered direct offering of shares and warrants | 2021-06-07 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-21 | Officer/Director Change; Exhibits | View | |
| 2026-10-15 | Regulation FD; Exhibits | View | |
| 2026-09-11 | Regulation FD; Exhibits | View | |
| 2026-09-09 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-16 | Regulation FD; Exhibits | View | |
| 2026-06-16 | Regulation FD; Exhibits | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-04-24 | Financial Obligation | View | |
| 2026-04-22 | Shareholder Vote | View | |
| 2026-04-07 | Material Agreement; Unregistered Equity Sales; Regulation FD; Exhibits | Agreement | View |
| 2026-04-07 | Officer/Director Change; Exhibits | View | |
| 2026-03-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-19 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Unregistere | Agreement | View |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-08 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-19 | Other Events | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR